The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
First-of-its-kind precision medicine test to predict a cancer patient’s response to an Immune Checkpoint Inhibitor (ICI)
Study to evaluate effectiveness of hypoglossal nerve stimulation
New biotechnology product aims to be world's fastest automatic sanitary solution
Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.
According to the state government, it will also provide support to special projects such as preclinical testing, genome sequencing in the private sector, private sector BSL-3 lab-vaccine development and manufacturing and testing and certification laboratories
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
Subscribe To Our Newsletter & Stay Updated
